Since the first report in 1981 of adrenergic innervation imaging with the radiotracer iodine-123 metaiodobenzylguanidine ( 123 I-mIBG), most cardiac work with it has focused on potential utility for assessing and managing patients who have heart failure with reduced ejection fraction (HFrEF) and associated lifethreatening ventricular arrhythmias. 1 In particular, the ability of 123 I-mIBG imaging to risk stratify HFrEF patients beyond what can be done with conventionally used clinical, ECG, and laboratory parameters promises to allow better guidance of invasive therapies such as implantable cardioverter defibrillators (ICDs) and left ventricular assist devices (LVAD), as well as assessment of the efficacy of pharmacologic therapies.
At the same time, much investigative work with 123 I-mIBG has also recognized its suitability for evaluating various other cardiac conditions, including ischemic heart disease. Adrenergic imaging in patients with coronary artery disease can provide unique insights because, in response to an ischemic insult, cardiac neurons behave differently from cardiac myocytes. Neurons have been shown to be more sensitive to oxygen deprivation than myocytes, 2 and thus in the setting of myocardial ischemia 123 I-mIBG defects can be present in the absence of perfusion tracer defects. 3 As sympathetic axons travel basal to apical in superficial epicardial layers alongside coronary arterial pathways before penetrating into myocardium, the conducting fibers are exposed to damage from local ischemia along the pathway, and thus there may be ischemic sympathetic damage apical to areas of myocyte injury. 4 Fallavollita and Canty have categorized such neuronal ischemic damage as dysinnervation defined as transient nerve dysfunction (also referred to as reversible neural stunning), or denervation defined as anatomic loss of fibers. 5 Finally, it takes from 8 to 17 weeks for ischemic injured neurons to recover from an insult, with 123 ImIBG defects reported to be present months after resolution of the ischemic episode. 6 Adrenergic image defects have been shown to persist longer than perfusion defects, 7, 8 and longer than defect on images using a fatty acid metabolic tracer such as iodine 123-b-Methyl-p-[ 123 I]-iodophenyl-pentadecanoic acid ( 123 I-BMIPP). 9 While 123 I-mIBG defects in the setting of infarction or chronic ischemic hibernation have been shown to be associated with increased risk of arrhythmias 7, 8, 10, 11 and may have patient management utility in this regard, imaging with 123 I-mIBG and related PET tracers has potential for assessing myocardial area at risk (AAR) in patients presenting with an acute coronary syndrome (ACS). In fact, use of radionuclide imaging to assess patients in this clinical setting, focusing on AAR and myocardial salvage after acute therapy, has been of interest since the advent of perfusion imaging. A 1981 report by Markis et al. of nine patients with acute MI showed that imaging after intracoronary injection of 201 Tl into the culprit artery before and again after intracoronary streptokinase could assess success of myocardial salvage as well as identify arterial reocclusion. 12 Also in 1981, Maddahi reported on the use of pre-thrombolytic therapy intravenous 201 Tl imaging followed by post-therapy intracoronary 201 Tl imaging in five patients with acute MI, demonstrating the ability to determine the extent of myocardial salvage as well as the potential use of the technique to predict ventricular functional improvement, i.e., residual viability, with potential therefore to guide subsequent revascularization (at that time limited to surgery). 13 Schofer et al. performed intracoronary injection of 201 Tl in 31 acute MI patients, 16 of whom also underwent simultaneous intracoronary injection of 99m Tc-pyrophosphate (PYP) to assess local necrosis, and found a correlation between image evidence of myocardial salvage and improvement in ejection fraction. 14 Of course, in the setting of an acute coronary event, use of 201 Tl that must be imaged immediately after injection is logistically difficult, especially in the current era of urgent intervention. The advent in the late 1980s of non-redistributing 99m Tc-sestamibi facilitated protocols in which tracer injection could occur during the acute event but with imaging postponed for a few hours until after patient stabilization, with the images still depicting myocardial AAR at the time of injection. The acute images can then be compared with imaging performed days later to assess myocardial salvage. In a study of dogs undergoing MI inducing acute coronary occlusions, in which image findings could be correlated with postmortem tissue analysis of infarct size, Verani et al. reported that 99m Tc-sestamibi imaging provided reliable demonstration of the presence of acute infarction, a good estimation of infarct size, and quantification of the extent of salvage myocardium after coronary reperfusion. 15 Wackers et al., 16 Gibbons et al., 17 and Santoro et al., 18 among others, demonstrated utility of this technique in people, with the latter study correlating image demonstrated myocardial salvage with ventricular functional recovery one month following the acute event.
From the onset, it was recognized that an advantage of a radionuclide image technique is that it depicts myocardial AAR differently from coronary anatomic methods. The latter generally involve sophisticated arithmetic and geometric algorithmic scoring methods based on vessel size and stenosis severity, but they do not account for the myriad of anatomic and physiologic factors, such as culprit stenosis shape and length, nonculprit distal stenoses and disease, vessel tone, collateral blood flow, and hemodynamic and metabolic variables, that determine AAR. Nuclear techniques integrate anatomy and physiology, and can show exactly how much myocardium is at risk at a given moment. In a study of 39 patients undergoing elective single-vessel coronary angiography who received intravenous 99m Tcsestamibi immediately before balloon inflation and again 24 to 48 hours later, Haronian et al. 19 found that nuclear perfusion image-derived AAR did not correlate well with that derived from anatomic algorithms. Christian et al. 20 studied 89 patients receiving acute intervention (thrombolytic therapy or angioplasty) for acute MI, with imaging after 99m Tc-sestamibi administration before reperfusion therapy and again about 1 week later, with a focus on using myocardium at risk and final infarct size to compare radionuclide with angiographic assessment of collateral flow. While there was a significant overall association between radionuclide and angiographic results, the correlation was held for anterior infarctions but not for smaller inferior infarctions possibly from the fact that in smaller infarctions collateral vessels may be less angiographically detectable.
More recently, radionuclide perfusion imagederived myocardial AAR has been used as a surrogate endpoint in at least 30 clinical acute MI trials. 21 Perfusion imaging was able to validate T2-weighed cardiac magnetic resonance (CMR) assessment of AAR, 22 and has served as a reference for assessing the validity of several anatomic angiographic score algorithms. 23 As introduced above, using adrenergic tracers to assess AAR during an ACS can be done, with studies showing important differences in the response of neuronal tissues to ischemic injury from that of cardiomyocytes. In key study by Matsunari et al. 24 involving 12 subjects without previous MI undergoing reperfusion therapy for an ACS, to assess AAR 99m Tcsestamibi was injected before revascularization with SPECT imaging performed 2 to 6 hours later. Infarct size was measured by a second resting 99m Tc-sestamibi study 4 to 9 days later. Sympathetic neuronal damage was assessed with 123 I-mIBG study performed 6 to 19 days after ACS onset. Figure 1 shows the typical pattern-infarct size based on post-MI imaging with perfusion tracers was significantly lower than AAR, while the post-MI 123 I-mIBG images were nearly identical to the initial AAR. Similarly, a study from the same lab by Simões et al. 8 of 67 post-MI patients imaged with 123 I-mIBG within 14 days of infarct onset, and studied with 201 Tl 2 to 4 days later, showed the mean post-MI adrenergic defect size to be larger than the post-MI perfusion defect size in 90% of patients, with a mean mismatch size of 10% ± 18% (range 0%-59%). Interestingly, the size of mismatch between adrenergic and perfusion images correlated with electrocardiographic (ECG) parameters-prolonged repolarization (i.e., higher heart rate-corrected QT interval) and evidence of delayed depolarization in the signal-averaged ECGconsidered to increase risk of ventricular arrhythmias, although in this small cohort event rates were too low to be significant. Thus, adrenergic imaging with 123 I-mIBG assesses an aspect of AAR different from perfusion tracers and therefore should provide unique insights into a patient's condition and future risk. From the few studies available it appears that adrenergic imaging can be performed conveniently several days after a revascularization intervention yet still depict how much myocardium was initially at risk. A question to be addressed is: in patients presenting with an ACS, how does 123 I-mIBG imaging-determined AAR relate to anatomic techniques, and could adrenergic imaging be a more effective tool to assess myocardial salvage provided by cardioprotective interventions? To explore this matter, in this issue of the Journal of Nuclear Cardiology, Vauchot et al. 25 correlate 123 I-mIBG image-determined AAR with that derived from the anatomic-modified APPROACH-score (ApAR) that is a semi-automatic quantification method based on the length and size of the branches of the culprit artery, validated in several studies 26, 27 and found to be useful for evaluating medical and interventional procedures to decrease infarct size. However, as described by Vauchot and colleagues, ApAR does not account for the many important anatomic and physiologic factors previously discussed, and does not provide models for branch vessel culprit lesions. The study protocol considered 96 patients without various clinical exclusion criteria who presented with acute ST-segment elevation myocardial infarction (STEMI) and were referred for primary PCI, but 20 patients with branch vessel culprit arteries and three others because of major collateral flow were excluded, and there were three refusals. In the final cohort of 70 patients who underwent 123 ImIBG imaging on a cadmium-zinc-telluride (CZT) camera 13 ± 7 days after PCI, for the 50 patients with an occluded culprit artery, the 123 I-mIBG area at risk (MAR) based on the summed dysinnervation score was highly correlated with the ApAR anatomic score, and also identified the same risk location regardless of how many other vessels had disease. However, for the 20 patients with a sub-occluded culprit artery there was no correlation with ApAR score that was most often higher than MAR (on average 4.5%), although risk locations were the same. Thus, AAR derived from an 123 I-mIBG imaging study that was done up to about a month after the infarct intervention was well in accord with risk area derived from a validated anatomic model, but the nuclear imaging technique exposed inadequacies of this anatomic model that had to exclude 23 of 96 patients initially and likely overestimated AAR in an additional 20 patients with a suboccluded artery. The authors conclude that 123 I-mIBG imaging often allows more accurate AAR assessment in patients whose arterial anatomic findings preclude applying standard algorithms, and could therefore potentially better test myocardial preservation techniques in acute MI patients whose culprit arteries have had some degree of spontaneous reperfusion. Tc-sestamibi prior to reperfusion with percutaneous coronary intervention, and infarct size was documented from repeat imaging 1 week later. 24 The defect in sympathetic nerve function assessed with MIBG was significantly larger than the area of infarction and was almost identical to the original extent of myocardial ischemia. Of course, data from many more patients are needed to establish the validity of and practical clinical uses of 123 I-mIBG-derived AAR. Correlation with CMR AAR that some people consider a suitable standard, needs to be done. Also required will be further understanding of the performance and interpretation of adrenergic imaging on solid-state cameras and exploration of PET tracers, both of which improve tomographic adrenergic image quality that is frequently poor for 123 I-mIBG acquired on standard gamma cameras, as well as definitive establishment of quantitative interpretation techniques that have important differences from those used for perfusion tracers. 29 Nevertheless, the theoretic basis of adrenergic imaging in ACS is sound, the images provide information different from coronary anatomic algorithms and perfusion images, and the technique can be broadly and conveniently performed after an acutely ill patient has been stabilized. Further potential for using adrenergic imaging in this clinical setting can be seen when one goes beyond 123 I-mIBG using PET tracers such as 11 Chydroxyephedrine, 11 C-epinephrine, and 11 C-phenylephrine that have been shown to depict different aspects of neuronal function, i.e., abnormalities of tracer uptake versus impairment of vesicular catecholamine storage in neurons in the infarct border zone. 30 Such imaging should therefore provide new insights into infarct site healing, remodeling, and electrophysiologic stability. The promise of adrenergic nuclear imaging to uniquely assess pathobiology during and after an acute ischemic event can make it a powerful tool for helping to improve the outcome of these patients.
